Mini Clinical Research Project - Analysis Report

Results:
The Device group showed a significant reduction in fasting blood glucose from baseline (avg: 160 mg/dL) to Week 12 (avg: 131 mg/dL).
The Control group showed only a minor reduction (avg: 162 $\rightarrow$ 157 mg/dL).

HbA1c: Device group reduced by ~0.3%, Control showed no significant change.

Adverse Events: Mild events reported in 2 participants, no severe adverse events.

Conclusion: The investigational device demonstrated good efficacy and safety in improving glycemic control over 12 weeks. Larger trials are recommended.